A decade ago, shares of Exelixis (EXEL -0.91%), a biotech company specializing in oncology, were trading for under $10 per share. Today, the drugmaker's shares are changing hands for about$45 apiece. In other words, Exelixis has crushed the market since 2015.Some might think there is little upside left for the stock after this run, but that's not the case. Read on to find out why Exelixis still has plenty of growth fuel left in the tank. Cabometyx is still doing the heavy liftingExelixis is best known for ...